Patient Registry Monitored Long-Term Safety and Efficacy of Increlex for Growth Deficiency
Background
Children with growth failure due to Primary Insulin-like Growth Factor-1 Deficiency (IGFD) often require treatment to support normal development. Increlex® (mecasermin), a recombinant human IGF-1, is an established therapy for this condition. However, comprehensive long-term safety and efficacy data in a real-world setting for this treatment remained crucial for understanding its full clinical profile.
Study Design
The primary objective was to monitor the safety profile, while a secondary objective focused on the efficacy of Increlex® replacement therapy in children with growth failure.
Results
The primary finding from the abstract is the successful establishment and enrollment of a large, 1378-patient registry to monitor Increlex® safety and efficacy, though specific results are not detailed in this record.
Key Findings
- The IGFD Registry successfully enrolled 1378 patients, creating a substantial cohort for long-term, real-world monitoring of Increlex® therapy in Primary Insulin-like Growth Factor-1 Deficiency.
- The registry operated for an 8-year period (2006-2014), designed to capture comprehensive long-term safety and efficacy data for Increlex® (mecasermin).
- It functioned as a critical Post-Authorisation Safety Study, aiming to provide insights into the real-world safety profile of Increlex® in children with growth failure.
- The primary objective was to monitor the safety of Increlex®, with a secondary focus on its effectiveness in treating growth failure associated with Severe Primary IGF-1 Deficiency.
Why It Matters
The continuation of similar monitoring efforts, as seen in the ongoing Increlex® Global Registry (NCT00903110), underscores the importance of continuous post-market surveillance for this patient population.